Dr. Med. Iris Loew-Friedrich, Chief Medical Officer of UCB and Executive Vice-President Global Projects and Development. ‘We are delighted about the beginning of the Phase 3 program. The progress designed to date encourages and motivates us as we work toward providing a fresh treatment option for women living with postmenopausal osteoporosis.’ Related StoriesDiet abundant with soy protein and isoflavones can protect menopausal ladies from osteoporosisTocilizumab drug presents potential treatment for patients with polymyalgia rheumaticsAnti-osteoporotic therapy can decrease subsequent fracture risks by 40 percent: StudyThe Phase 3 program carries a multicenter, worldwide, randomized, double-blind, placebo-controlled, parallel-group, two-year study in a lot more than 5,000 postmenopausal women with osteoporosis.‘To be successful, any policy alternative should support a nuanced view of the value of medication therapy in improving wellness outcomes and reducing costs.’ To view the full article, go to the Health Affairs site at:.. Biodesix, Kadmon enter Stage 3 non-little cell lung cancer research collaboration Biodesix Inc. It incorporates an exploratory evaluation using VeriStrat, a available commercially, blood-based test that’s currently used to greatly help doctors guide treatment for individuals with non-little cell lung tumor. VeriStrat testing will end up being performed on serum samples from the analysis to measure the test’s utility in determining sufferers with better or even worse outcomes pursuing treatment with KD019.